SCHEMBL8305630

SCHEMBL8305630

C=C/C=C\N=C/C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18598702 0.75
SCHEMBL21858924 0.73
SCHEMBL21516031 0.73
SCHEMBL13344655 0.71
SCHEMBL18404566 0.71
SCHEMBL10074492 0.71
SCHEMBL12190584 0.71
SCHEMBL25731729 0.69
SCHEMBL23510726 0.69
SCHEMBL18731442 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365502-A1 METHOD FOR PREPARING PYRIDINE COMPOUND SUBSTITUTED WITH TRIFLUOROMETHYLTHIO, DIFLUOROMETHYLTHIO OR TRIFLUOROMETHYL IN META POSITION NANKAI UNIVERSITY (CN) 2023-11-16 US disclosed
US-20230322816-A1 PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-10-12 US disclosed
EP-3652164-B1 PHENYLACETAMIDES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2023-06-21 EP disclosed
US-20220315569-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE BRISTOL MYERS SQUIBB CO (US) 2022-10-06 US disclosed
US-20220185827-A1 PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-06-16 US disclosed
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 EP disclosed
US-11230520-B2 Silylations of aromatic substrates with base-activated organosilanes CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-01-25 US disclosed
EP-3912981-A1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-11-24 EP disclosed
WO-2021224489-A1 NOVEL COMPOUNDS FOR DIAGNOSIS AC IMMUNE SA (CH) 2021-11-11 WO disclosed
WO-2021216656-A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
US-8629162-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-14 US disclosed
US-20130035327-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED 2013-02-07 US disclosed
US-8354427-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICAL INCORPORATED (US) 2013-01-15 US disclosed
EP-2295047-A2 Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders Schering Corporation (US) 2011-03-16 EP disclosed
EP-1812440-B1 PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2010-09-22 EP disclosed
US-20100184739-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 US disclosed
WO-2007062230-A2 NUCLEAR RECEPTOR BINDING AGENTS GTX, INC. (US) 2007-05-31 WO disclosed
WO-2007047293-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS SCHERING CORPORATION (US) 2007-04-26 WO disclosed
US-7166859-B2 Organic semiconductor transistor element, semiconductor device using the same, and process for producing the semiconductor device FUJI XEROX CO., LTD. (JP) 2007-01-23 US disclosed
WO-2005019200-A2 ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-03-03 WO disclosed